TMS clinic marketing: FDA indications, claims, ad platform rules and safety copy

Transcranial magnetic stimulation, or TMS, is a device-based treatment, and that shapes how a clinic can talk about it. The FDA authorizes each TMS device for specific uses, the FTC Act governs what the clinic claims about results, ad platforms restrict how health services are targeted and worded, and the screening forms a clinic uses collect mental health information. This guide covers what a TMS clinic or a practice adding TMS needs to get right in its website, ads and intake.

Several neighboring topics have their own guides and are not repeated here. Telehealth prescribing, Google certification for online prescribing, 42 CFR Part 2 and placing the 988 Suicide and Crisis Lifeline on every page are covered in psychiatric practice marketing. Ketamine and esketamine status, the REMS and Schedule III rules are covered in ketamine clinic marketing. Patient stories are covered in patient testimonials and before-and-after photos, ad pixels on health pages in tracking pixels on practice websites, and price display in advertising cash prices. EEG-based services such as neurofeedback have a different FDA record, covered in our guide to neurofeedback and qEEG clinic marketing.

Know exactly what FDA authorized for your device

TMS devices are regulated as class II medical devices, and the FDA classification regulations that name them include these three. Under 21 CFR 882.5805, a repetitive transcranial magnetic stimulation system is identified as a device that delivers pulsed magnetic fields “to treat the symptoms of major depressive disorder without inducing seizure in patients who have failed at least one antidepressant medication and are currently not on any antidepressant therapy.” That identification dates from 2011 (76 FR 44491). A second regulation, 21 CFR 882.5802, added in 2019 (84 FR 9230), covers TMS systems “for neurological and psychiatric disorders and conditions.” A third, 21 CFR 882.5808, covers a transcranial magnetic stimulator for headache.

The FDA’s own account of the timeline is in its news release of August 17, 2018: the agency “permitted marketing of TMS as a treatment for major depression in 2008 and expanded the use to include TMS for treating pain associated with certain migraine headaches in 2013,” and on that date permitted marketing of a TMS system for obsessive compulsive disorder through the De Novo pathway. In the FDA product classification database, these uses sit under separate product codes: OBP for major depressive disorder, QCI for obsessive compulsive disorder, and OKP for migraine headache.

The regulation is not the indication. Each device reaches the market through its own 510(k) clearance or De Novo authorization, and each record carries an indications for use statement written for that device. The wording, the patient population and any conditions in it can differ from one device to another and can change when a manufacturer gets a new clearance. Before you write a service page, look up the exact device and model you own in the FDA 510(k) or De Novo database, save the indications for use statement with the date you checked it, and write your copy from that text. A use your device is authorized for is not proof that another clinic’s device, or a newer model of yours, carries the same wording.

Cleared, authorized, approved: use the FDA’s own word

The FDA uses different words for different pathways, and the difference matters in an ad. For a device that reaches the market through a 510(k) premarket notification, 21 CFR 807.97 is direct about what that means: a substantial equivalence determination “does not in any way denote official approval of the device,” and “any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding.”

The FTC makes the same point from the advertising side. Example 49 in its Health Products Compliance Guidance describes a class II device cleared for one purpose and advertised as “FDA Approved” next to dramatic results claims, and finds the ad deceptive because the juxtaposition gives the impression that the FDA found the product effective for those effects. Two practical rules follow. Describe the regulatory status in the terms the FDA record uses for your device, and keep that description attached to the specific indication it covers, not placed next to broader claims about what treatment will do.

Uses outside the listed indications

A clinician may decide, in the care of one patient, to use a device in a way its labeling does not describe. Advertising that use is a different question. Under 21 CFR 801.4, the intended uses of a device can be shown by “labeling claims, advertising matter, or oral or written statements” by the people responsible for its labeling or their representatives. Google’s Healthcare and medicines policy does not allow the “promotion of speculative and/or experimental medical treatments.” And under the FTC Act, any claim that treatment helps a condition needs proof whether or not a device is authorized for it.

For a clinic, the safe pattern is simple. Build service pages and ads only around the indications listed for your device. If you also treat patients for other conditions based on clinical judgment, talk to counsel before mentioning those conditions anywhere in marketing, and do not build landing pages or ad groups around them.

Claims about results need proof

The FTC Act makes it unlawful to disseminate a false advertisement to induce the purchase of “food, drugs, devices, services, or cosmetics” (15 U.S.C. 52), and 15 U.S.C. 55 defines a false advertisement as one “misleading in a material respect,” taking into account what it fails to reveal. Deceptive practices in general are unlawful under 15 U.S.C. 45. The FTC Health Products Compliance Guidance says health benefit claims need competent and reliable scientific evidence, that this “will need to be in the form of randomized, controlled human clinical testing” as a general matter, and that results must be statistically significant and clinically meaningful. The FTC judges an ad by its net impression, so an implied claim counts as much as a stated one.

Response and remission figures need extra care. A figure from a device’s clinical study describes that study population, under that study’s protocol, compared with a sham device. If you quote one, quote it exactly, name the source and date, describe what was measured, and do not present it as what patients at your clinic should expect. Your own clinic’s numbers are not a substitute for controlled evidence, and a page that mixes the two invites the wrong impression.

Rewrites that keep copy inside the evidence:

• Instead of “TMS works when medication fails,” describe the indication your device’s FDA record lists, in its words, and invite the reader to ask whether they are a candidate.
• Instead of “lasting relief from depression,” describe the treatment itself: what a session involves, who supervises it and how the course is planned.
• Instead of a headline percentage with no context, either leave it out or quote the study exactly with its source, population and comparison.
• Instead of “drug-free cure,” say that TMS is a non-drug treatment and that the clinician will discuss whether it fits alongside the patient’s other care.

Patient stories

The endorsement rules apply to TMS clinics the same way they apply elsewhere. Under 16 CFR 255.2, “consumer endorsements themselves are not competent and reliable scientific evidence,” and a story about a key result is likely to be read as what patients will generally achieve. Without proof that the story is representative, the ad has to clearly disclose the generally expected performance. For mental health care in particular, think hard about whether a patient story serves the reader at all, and see our testimonials guide for consent and disclosure.

Ad platforms: write about the service, not the reader

Meta’s Privacy Violations and Personal Attributes standard says ads “must not contain content that asserts or implies personal attributes,” and the list includes “physical or mental health (including medical conditions).” An ad that opens with “Are you struggling with depression?” or “Still depressed after trying medication?” implies the reader’s condition. Describe the service instead: what TMS is, who provides it at your clinic and how to book a consultation. Meta’s Health and Wellness standard also says ads for “dietary, health, or weight loss or weight gain products and services must be targeted to people at least 18 years or older,” and bars clickbait such as “promises of specific outcomes within a set timeframe without disclaimers or qualifiers.”

On Google, health is one of the sensitive interest categories in the Personalized advertising policy, and advertisers promoting in those categories “are unable to use advertiser-curated audiences,” which include customer match and your own data segments. In practice, that means you build TMS campaigns from search terms and location, not from a list of patients or website visitors. Our guide to Facebook and Instagram ads for practices covers the platform setup in more detail.

Safety information belongs on the page

Because 15 U.S.C. 55 looks at what an ad fails to reveal, a page that describes benefits should also describe what the patient should know before treatment. The FDA’s special controls in 21 CFR 882.5802 require device labeling to include the risks and benefits, “detailed instructions to prevent seizures” and a description of the ear protection patients wear. The FDA’s 2018 release, describing one device, listed contraindications for metallic objects or implanted stimulator devices in or near the head and said patients with a history of seizures should discuss it with their provider.

You do not need to reproduce device labeling on a marketing page, but you should not leave a reader thinking there is nothing to check. A short section that says a clinician screens every patient before treatment, names the questions they ask about implants, metal and seizure history, and points to the device’s patient labeling for the full list, does the job. Write it from your own device’s labeling, not from another device’s.

A TMS clinic is not a crisis service

TMS is a scheduled outpatient treatment, and the marketing should say so plainly. On every page that discusses depression or obsessive compulsive disorder, state that the clinic does not provide emergency care and show the 988 Suicide and Crisis Lifeline, which people can call or text at 988. Our psychiatric practice guide covers where to place it and how to word it.

Course length, prices and insurance

A treatment course is planned by the clinician for each patient, and copy that promises a fixed number of sessions or a fixed timeline to results can mislead. If you publish a session count, say whose protocol it comes from and that the clinician sets the plan. If you publish prices, show what they include and exclude, as our cash price guide explains. If you list insurance, list plans you are actually in network with and say that coverage depends on the plan’s own criteria; our insurance accepted page guide covers that page.

Screening forms and privacy

TMS intake forms collect mental health history and can include a rating scale score. That is health information, and under 45 CFR 160.103 a health care provider that transmits health information electronically in connection with a covered transaction, such as an insurance claim, is a HIPAA covered entity. Keep ad pixels, session recording and chat widgets that send data to third parties off intake and screening pages, and check what the form tool does with the answers. The tracking pixels guide and the HIPAA marketing rules guide cover the details.

Illustration: two service pages

Illustration: a clinic owns one TMS device whose FDA record lists major depressive disorder. Its first draft headline reads “FDA approved TMS that finally works.” Its device came through a 510(k), and the clinic has no controlled evidence for the implied promise. The revised page uses the indication wording from the device’s record, describes the regulatory status in the FDA’s terms next to that indication only, describes a session and the screening questions, shows 988 and a no-emergency-care line, and invites readers to book a consultation to see whether they are a candidate.

Illustration: a clinic wants to add landing pages for several conditions that are not in its device’s indications for use, because staff have read about research. The revised plan keeps service pages and ad groups to the listed indication, adds an educational page about what TMS is that makes no claims about unlisted conditions, and sends the question of any further mention to counsel first.

Checklist

• Look up your exact device and model in the FDA 510(k) or De Novo database and save the indications for use statement with the date.
• Write service pages from that statement, in its words, and only for the indications it lists.
• Describe regulatory status in the FDA’s own terms for your device, attached to the listed indication only.
• Do not write “FDA approved” for a device that came through a 510(k).
• Keep unlisted conditions out of ads, ad groups and landing pages unless counsel has cleared it.
• Back every results claim with competent and reliable scientific evidence; quote study figures exactly with source, population and comparison.
• Write ads about the service, not the reader’s condition, and target health ads to adults on Meta.
• Do not build Google health campaigns from customer lists or site visitor segments.
• Add a screening and safety section written from your device’s labeling.
• Show 988 and a no-emergency-care line on pages about depression or OCD.
• Keep ad pixels and third-party scripts off intake and screening pages.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses. For a TMS clinic, we can build a website with service pages written from your device’s indications for use, a screening and safety section and 988 placement, and set up local search so people nearby find an accurate description of the treatment. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• 21 CFR 882.5805: Repetitive transcranial magnetic stimulation system
• 21 CFR 882.5802: Transcranial magnetic stimulation system for neurological and psychiatric disorders and conditions
• 21 CFR 882.5808: Transcranial magnetic stimulator for headache
• 21 CFR 807.97: Misbranding by reference to premarket notification
• 21 CFR 801.4: Meaning of intended uses
• FDA product classification: product code OBP
• FDA product classification: product code QCI
• FDA product classification: product code OKP
• FDA 510(k) premarket notification database
• FDA De Novo database
• FDA news release, August 17, 2018: TMS for obsessive compulsive disorder
• 15 U.S.C. 45: Unfair or deceptive acts or practices
• 15 U.S.C. 52: Dissemination of false advertisements
• 15 U.S.C. 55: Additional definitions, including false advertisement
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.2: Consumer endorsements
• 45 CFR 160.103: Definitions, including covered entity
• Google Ads: Healthcare and medicines policy
• Google Ads: Personalized advertising policy
• Meta: Health and Wellness ad standard
• Meta: Privacy Violations and Personal Attributes ad standard
• 988 Suicide and Crisis Lifeline

More in Mental and behavioral health marketing